Donald L. Zuhn, Jr. is a partner with McDonnell Boehnen Hulbert & Berghoff LLP and serves as Chair of the firm’s Biotechnology & Pharmaceuticals Practice Group. Dr. Zuhn has more than a decade of experience in all aspects of patent prosecution, litigation, counseling, and licensing. He represents a variety of clients, including biotechnology and pharmaceutical companies both large and small, and universities.
Dr. Zuhn joined MBHB in 1998. He maintained a full-time position as a law clerk while attending law school at night until his graduation in 2002.
Ph.D., University of Illinois at Chicago,
Mammalian Genetics; Doctoral Research: Analysis of the structure and function of protein domains of human P-glycoprotein through the use of genetic suppressor elements encoding antisense RNA molecules and truncated proteins
B.S., Loyola University Chicago,
J.D., The John Marshall Law School,
Summa Cum Laude, Fred F. Herzog Scholarship; Dean’s Scholarship; John N. Jewitt Scholarship; The John Marshall Law Review, Review of Intellectual Property Law, Lead Articles Editor
U.S. Patent & Trademark Office
IAM Patent 1000
IAM Strategy 300 — The World’s Leading IP Strategists
IAM Global Leaders Guide
Best Lawyers in America
JD Supra Readers’ Choice Awards
Managing IP Stars
LMG Life Sciences Stars
Founding author and editor of the Patent Docs weblog, a site focusing on biotechnology and pharmaceutical patent law.
Donald L. Zuhn, Jr. and Paul H. Berghoff, “The Evolution of the Written Description Requirement in the Context of Biotechnological Inventions”, Midwestern Biotech Intellectual Property Law Symposium, June 2004.
Kevin E. Noonan, Michael S. Greenfield, and Donald L. Zuhn, “Paradise Lost: The Uncertain Future of Research Tool Patents”, Intellectual Property & Technology Law Journal, March 2003.
“DNA Patentability: Shutting the Door to the Utility Requirement”, The John Marshall Law Review, Summer 2001.